The effect of ferric citrate on heart failure

Hamano Takayuki0 个研究点目标入组 162 人开始时间: 2023年2月8日最近更新: 2023年11月20日

适应症

试验速览

暂无简介。

•1.Age 20 years or older
•2.Heart failure with left ventricular ejection fraction less than 50%
•3.Iron deficiency, defined by ferritin less than 100 ng/mL or ferritin less than 300 ng/mL and transferrin
•saturation less than 20%
•4. Mild anemia (Hb>=10g/dL and Hb<13g/dL in men, Hb<12g/dL in women
•5.Those who can perform cardiopulmonary exercise test
•6.Those on the stable dose of medications for heart failure including RAS inhibitors, SGLT2 inhibitors,beta-blockers, or ARNI for more than 2 months
•7. Those who consented for participation in this research

•1.Hemoglobin less than 10g/dL, decrease in hemoglobin more than 1g per month
•2.History of gastrointestinal bleeding, surgery, or transfusion within 3 months
•3.Expecting surgery in next 4 months
•4.Pregnant or lactating women and women who intend to be pregnant
•5.Those who are already receiving oral or intravenous iron treatment
•6.Those who have experienced serious adverse events by oral iron in the past
•7.Chemotherapy for malignancy
•8.Hematological malignancy including myelodysplastic syndrome
•9.Those on dialysis
•10. Those on erythropoiesis stimulating agents or hypoxia-inducible factor prolyl hydroxylase inhibitors
•11.Those who were considered to be inappropriate to participate in the study by treating physicians

发起方

Hamano Takayuki